雷貝拉唑三聯(lián)療法治療幽門螺桿菌相關(guān)十二指腸潰瘍的臨床療效

曾貴利+李濤

[摘要] 目的 探討雷貝拉唑三聯(lián)療法治療幽門螺桿菌相關(guān)十二指腸潰瘍的臨床療效。方法 方便選取2015年6—12月該院消化內(nèi)科收治的幽門螺桿菌陽(yáng)性的十二指腸潰瘍患者80例作為觀察對(duì)象。采用隨機(jī)數(shù)表法將所有患者分為觀察組與對(duì)照組，對(duì)照組40例患者采用常規(guī)奧美拉唑、阿莫西林、克拉霉素藥物治療，觀察組40例患者則采用阿莫西林、克拉霉素聯(lián)合雷貝拉唑治療，比較兩組患者藥物治療效果，并對(duì)比兩組患者幽門螺桿菌根除率，隨訪復(fù)發(fā)率以及不良反應(yīng)發(fā)生結(jié)果。 結(jié)果 觀察組患者治療后的總有效率為95.00%、幽門螺桿菌根除率為90.00%，明顯高于對(duì)照組的77.50%、72.50%（P<0.05），但兩組患者不良反應(yīng)發(fā)生率比較差異無(wú)統(tǒng)計(jì)學(xué)意義（P>0.05）；并且隨訪1年結(jié)果顯示觀察組患者幽門螺桿菌相關(guān)十二指腸潰瘍復(fù)發(fā)率（5.00%）明顯低于對(duì)照組復(fù)發(fā)率（25.00%），差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。 結(jié)論 采用雷貝拉唑三聯(lián)療法治療幽門螺桿菌相關(guān)十二指腸潰瘍臨床療效顯著，并且患者幽門螺桿菌根除率較高，治療后不易復(fù)發(fā)，可作為幽門螺桿菌陽(yáng)性的十二指腸潰瘍患者首選藥物治療方案。

[關(guān)鍵詞] 雷貝拉唑三聯(lián)療法；幽門螺桿菌；十二指腸潰瘍；臨床療效

[中圖分類號(hào)] R4 [文獻(xiàn)標(biāo)識(shí)碼] A [文章編號(hào)] 1674-0742（2017）03（b）-0147-03

[Abstract] Objective To study the clinical curative effect of triple therapy of rabeprazole in treatment of helicobacter pylori associated duodenal ulcers. Methods 80 cases of patients with helicobacter pylori associated duodenal ulcers admitted and treated in the digestive system department in our hospital from June to December 2015 were convenient selected and randomly divided into two groups with 40 cases in each， the control group adopted the routine treatment of omeprazole， amoxicillin and clarithromycin， while the observation group adopted the triple therapy of omeprazole， amoxicillin and clarithromycin， and the drug treatment effect was compared between the two groups， and the eradication rate of helicobacter pylori， recurrence rate of follow-up and adverse reactions were compared between the two groups. Results The total effective rate and eradication rate of helicobacter pylori after treatment in the observation group were obviously higher than those in the control group， （95.00%， 90.00% vs 77.50%， 72.50%），（P<0.05）， but the difference in the incidence rate of adverse reactions between the two groups had no statistical significance（P>0.05）， and the 1-year follow-up results showed that the recurrence rate in the observation group was obviously lower than that in the control group（5.00% vs 25.00%）， and the difference had statistical significance（P<0.05）. Conclusion The clinical curative effect of triple therapy of rabeprazole in treatment of helicobacter pylori associated duodenal ulcers is obvious with higher eradication rate of helicobacter pylori， and it is hard to recrudesce， which can be used as the primary drug treatment plan of positive patients with helicobacter pylori associated duodenal ulcers.

[Key words] Triple therapy of rabeprazole； Helicobacter pylori； Duodenal ulcers； Clinical curative effect

十二指腸潰瘍是臨床上最為常見(jiàn)的消化性潰瘍之一，相關(guān)調(diào)查顯示十二指腸潰瘍發(fā)病率在所有消化性潰瘍中僅次于胃潰瘍，患者主要表現(xiàn)為周期性、節(jié)律性的上腹部疼痛、腹脹、惡心、反酸等，當(dāng)治療不及時(shí)或病情較重時(shí)可導(dǎo)致潰瘍出血、穿孔等不良臨床結(jié)局的發(fā)生[1]?，F(xiàn)有臨床研究結(jié)果證實(shí)，幽門螺桿菌感染是導(dǎo)致胃潰瘍、十二指腸潰瘍發(fā)生的重要原因之一，而臨床治療也以抑制胃酸分泌、抗幽門螺桿菌感染為主，目前質(zhì)子泵抑制劑聯(lián)合抗生素三聯(lián)療法治療十二指腸潰瘍是較為常用的手段，但藥物應(yīng)用方案相對(duì)較多，療效以及藥物應(yīng)用的安全性方面也存在較大的差異[2-3]。為進(jìn)一步提升幽門螺桿菌相關(guān)十二指腸潰瘍的臨床治療效果，該組研究通過(guò)對(duì)2015年6—12月該院收治80例患者進(jìn)行隨機(jī)對(duì)照分析，探討雷貝拉唑三聯(lián)療法治療幽門螺桿菌相關(guān)十二指腸潰瘍的臨床療效，現(xiàn)報(bào)道如下。